Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences, Inc. - Common Stock (NQ: RNA )

30.10 -0.83 (-2.68%)
Streaming Delayed Price Updated: 9:43 AM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Avidity Biosciences Touts Encouraging Data From Myotonic Dystrophy Type 1 Study
Avidity Biosciences Inc (NASDAQ: RNA) announced  
Via Benzinga
After Falling 18% in 1 Day, Is This Growth Stock Done For?
It's too soon to predict doom, but that doesn't mean things are good. 
Via The Motley Fool
The Latest Analyst Ratings for Avidity Biosciences
Via Benzinga
Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Expert Ratings for Avidity Biosciences
Via Benzinga
Why Avidity Biosciences Shares Are Sliding Today
Via Benzinga
Expert Ratings for Avidity Biosciences
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
Expert Ratings for Avidity Biosciences
Via Benzinga
Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key Study
The company is working on a treatment for an inherited muscle-wasting disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Peering Into Avidity Biosciences's Recent Short Interest
Avidity Biosciences's (NASDAQ:RNA) short percent of float has fallen 26.62% since its last report. The company recently reported that it has 6.51 million shares sold short, which is 11.33% of all... 
Via Benzinga
EXCLUSIVE: The Benzinga Moneymaker Series, 5 Emerging Stocks For Investors To Watch
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. The rise of social media and retail traders gave way to countless methods to uncover new information.... 
Via Benzinga
Novavax, Tesla, Western Digital And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Tesla, Amazon, Novavax, Lennar Corp, Avidity Biosciences: Why These 5 Stocks Are Drawing Retail Investors' Attention Today
Major Wall Street indices closed in the red on Wednesday despite an anticipated 50 basis points hike by the Federal Reserve as Chair Jerome Powell indicated the need for more data before the central... 
Via Benzinga
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision. 
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Avidity Biosciences (NASDAQ: RNA) Posts Positive Phase 1/2 MARINA Data on AOC 1001, Announcing the First Successful Delivery of RNA to Muscle
Avidity Biosciences, Inc. (NASDAQ: RNA) is engaged as a biopharmaceutical company, which is focused on developing a new class of 
Via Spotlight Growth
How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere
The company tested its efforts in myotonic dystrophy 1, a form of muscular dystrophy. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
What's Going On With Avidity Biosciences Stock?
Avidity Biosciences Inc (NASDAQ: RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the first-ever successful 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.